We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?
Read MoreHide Full Article
Germany-based Bayer AG (BAYRY - Free Report) is rumored to raise its offer price yet again for the proposed acquisition of Monsanto Company in a deal that will create a global leader in agriculture. This time, the life science company will supposedly offer $129 per share to the agriculture giant for a potential buyout.
Last week, Bayer reported that its talks with Monsanto had advanced and that it had sweetened its offer to $127.50 a share from the previously proposed $125. However, no key terms and conditions were agreed upon. Bayer had also mentioned that there was no guarantee even then that the parties would finally enter into an agreement at all.
We remind investors that Monsanto’s management had been openly opposed to a takeover. In May 2016, the company rejected Bayer’s initial acquisition offer of $122 per share in an aggregate all-cash deal, worth $62 billion, citing that it would significantly undervalue Monsanto. Bayer followed up with an increased offer of $125 per share in July, in a bid to address Monsanto’s questions regarding financing and regulatory matters.
The deal is expected to bring together leading platforms like Seeds & Traits, Crop Protection, Biologics and Digital Farming. The combined business will benefit from Monsanto’s Seeds & Traits and Bayer’s Crop Protection products across a comprehensive range of indications and crops. The transaction will also create attractive opportunities for the employees of both the companies.
We expect investor focus to remain on updates from the Bayer/Monsanto transaction, going ahead.
Currently, both Bayer and Monsanto carry a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Anika Therapeutics, Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?
Germany-based Bayer AG (BAYRY - Free Report) is rumored to raise its offer price yet again for the proposed acquisition of Monsanto Company in a deal that will create a global leader in agriculture. This time, the life science company will supposedly offer $129 per share to the agriculture giant for a potential buyout.
Last week, Bayer reported that its talks with Monsanto had advanced and that it had sweetened its offer to $127.50 a share from the previously proposed $125. However, no key terms and conditions were agreed upon. Bayer had also mentioned that there was no guarantee even then that the parties would finally enter into an agreement at all.
BAYER A G -ADR Price
BAYER A G -ADR Price | BAYER A G -ADR Quote
We remind investors that Monsanto’s management had been openly opposed to a takeover. In May 2016, the company rejected Bayer’s initial acquisition offer of $122 per share in an aggregate all-cash deal, worth $62 billion, citing that it would significantly undervalue Monsanto. Bayer followed up with an increased offer of $125 per share in July, in a bid to address Monsanto’s questions regarding financing and regulatory matters.
The deal is expected to bring together leading platforms like Seeds & Traits, Crop Protection, Biologics and Digital Farming. The combined business will benefit from Monsanto’s Seeds & Traits and Bayer’s Crop Protection products across a comprehensive range of indications and crops. The transaction will also create attractive opportunities for the employees of both the companies.
MONSANTO CO-NEW Price
MONSANTO CO-NEW Price | MONSANTO CO-NEW Quote
We expect investor focus to remain on updates from the Bayer/Monsanto transaction, going ahead.
Currently, both Bayer and Monsanto carry a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Anika Therapeutics, Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>